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Members of the cullin and RING finger ROC protein families form heterodimeric complexes to constitute
a potentially large number of distinct E3 ubiquitin ligases. We report here that the highly conserved C-terminal
sequence in CUL1 is dually required, both for nuclear localization and for modification by NEDD8. Disruption
of ROC1 binding impaired nuclear accumulation of CUL1 and decreased NEDD8 modification in vivo but had
no effect on NEDD8 modification of CUL1 in vitro, suggesting that ROC1 promotes CUL1 nuclear accumu-
lation to facilitate its NEDD8 modification. Disruption of NEDD8 binding had no effect on ROC1 binding, nor
did it affect nuclear localization of CUL1, suggesting that nuclear localization and NEDD8 modification of
CUL1 are two separable steps, with nuclear import preceding and required for NEDD8 modification. Disrupt-
ing NEDD8 modification diminishes the IkBa ubiquitin ligase activity of CUL1. These results identify a
pathway for regulation of CUL1 activity—ROC1 and the CUL1 C-terminal sequence collaboratively mediate
nuclear accumulation and NEDD8 modification, facilitating assembly of active CUL1 ubiquitin ligase. This
pathway may be commonly utilized for the assembly of other cullin ligases.
Ubiquitin-mediated proteolysis plays a key role in regulating
the levels of a large number of proteins involved in diverse
cellular processes. Through a cascade of enzymes involving
ubiquitin activation (E1), conjugation (E2), and ligation (E3),
the ubiquitin-dependent protein degradation pathways cata-
lyze the formation of polyubiquitin chains onto substrate pro-
teins via isopeptide bonds. Polyubiquitinated substrates are
then rapidly delivered to and degraded by the 26S proteasome
(6, 7, 12). While E1 and E2 both represent structurally related
proteins that are relatively well characterized biochemically,
the E3 ubiquitin ligases, generally defined as having both a
ubiquitin ligase activity and a substrate targeting function,
comprise a potentially large number of diverged multisubunit
protein complexes. Elucidating the molecular nature and reg-
ulation of E3s has become critically important to our under-
standing of regulated proteolysis and is currently the focus of
intensive investigation.
The three best-characterized E3 activities involve HECT
(homologous to E6AP carboxy terminus) domain proteins rep-
resented by E6-AP (10), the anaphase-promoting complex
(APC or cyclosome) that consists of at least 12 subunits and is
required for both entry into anaphase and exit from mitosis
(18, 51), and the SCF complexes, which consist of SKP1,
CDC53 or its homologue, Cullin-1, and a distinct F box protein
(1, 4, 42). A core subunit of SCF, cullin or CDC53, was first
identified, through genetic analysis, in Caenorhabditis elegans
and yeast as being encoded by a gene whose functional loss
caused defects in G1 regulation (19, 29, 47). Several CDC53- or
CUL1-dependent SCF complexes have been identified in both
yeast and mammalian cells that function to ubiquitinate many
phosphorylated substrate proteins, indicating that a similar
SCF mechanism is evolutionarily conserved across species (re-
cently reviewed in references 2, 20, and 36). A subunit of the
mitotic APC E3 complex, APC2, was found to contain a lim-
ited sequence similarity to CDC53 and cullins (50, 52), further
underscoring an important and conserved role for cullin pro-
teins in ubiquitin-mediated proteolysis.
Recently a family of closely related RING finger proteins,
represented by ROC1 (regulator of cullins, also known as Rbx1
for RING-box protein, or Hrt1) was identified (reviewed in
references 2 and 51). ROC1 shares a high degree of sequence
similarity to another APC subunit, APC11, and functions as an
essential subunit of CUL1 and CDC53 ubiquitin ligases to
catalyze ubiquitination of the phosphorylated inhibitor of the
NF-kB transcription factor, IkBa, G1 cyclin Cln2, and the
CDK inhibitor Sic1 (17, 33, 41, 43, 45). Deficiency of yeast
ROC1 can be functionally rescued by mammalian ROC1 and
ROC2 but not by yeast APC11 (17, 33, 41), demonstrating an
evolutionary conservation and functional specificity for the
ROC gene family. ROC1 and ROC2 commonly interact with
all cullins to constitute multiple active ubiquitin ligases, while
APC11 specifically interacts and constitutes active ligase with
cullin-related APC2 (33; Ohta et al., unpublished data), sug-
gesting the in vivo existence of a potentially large number of
heterodimeric cullin-ROC ubiquitin ligases. More recently,
several large RING finger proteins with otherwise diverse
structures and functions were linked to ubiquitination (14, 26),
suggesting a broad and general function of RING fingers in
inducing E3 ligase activity.
Genetic and biochemical studies with yeast cells have iden-
tified a covalent modification of the CDC53 protein by a ubiq-
uitin-like protein, RUB1 (related to ubiquitin), via an E1-like
bipartite RUB1-activating enzyme (22, 24). In mammalian
cells, catalyzed via a similar bipartite E1 activity and E2-Ubc12
(34), the RUB1 homologue, NEDD8 (neural precursor cell-
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expressed and developmentally down-regulated), forms a co-
valent conjugate with most, if not all, cullins (9, 23, 34). In fact,
cullins appear to be the major cellular substrates of NEDD8
modification (15, 22, 24, 34). NEDD8 is a member of a group
of ubiquitin-like proteins that are covalently linked to their
substrates mostly, if not only, monomerically by E1 activating
and E2 conjugating activities distinct from that utilized in ubiq-
uitination (8, 13). Conjugation of the mammalian ubiquitin-
related UCRP (ubiquitin cross-reactive protein) appears to
target conjugates to the cytoskeleton (25), and conjugation of
another mammalian ubiquitin-like protein, SUMO-1 (small
ubiquitin-related modifier, also known as sentrin, PIC1, UBL1,
and GMP1), was found to target cytosolic RanGAP1 to the
nuclear pore complex (27, 30), to antagonize ubiquitin-medi-
ated degradation of IkBa (3), and to activate transcriptional
activity of p53 (5, 40). These observations indicate that in
contrast to polyubiquitination, covalent modification by these
ubiquitin-like proteins plays regulatory, rather than proteo-
lytic, roles.
The regulation and biochemical significance of cullin-RUB1
or -NEDD8 conjugation are not clear at present. The RUB1
gene and its E1 (ENR2 and UBA3) activating and E2
(UBC12) conjugating genes are not essential for budding yeast
growth. The defect in CDC53-RUB1 conjugation, however, is
synthetically lethal, with a temperature-sensitive mutation of
cdc34 that enhances the phenotype of the cdc4, cdc53, and skp1
mutations (22, 24), leading to the suggestion that RUB1 may
play a regulatory role, albeit nonessential, in regulating ROC-
cullin ubiquitin ligase activity in budding yeast. Disruption of
NEDD8 modification in both mammalian and fission yeast
cells, however, significantly reduced the level of in vitro SCF
ubiquitin ligase activity of CUL1 and resulted in a cellular
lethality (32, 35, 37, 39), indicating an essential function of
NEDD8 modification. NEDD8 modification of both yeast
CDC53 and human CUL2 is dependent on the presence of
ROC1 (16). The mechanism by which ROC1 activates RUB1
and NEDD8 modification of cullins is unclear. In this paper,
we report that the highly conserved cullin C-terminal sequence
and binding with ROC1 are both required for efficient nuclear
accumulation of cullin. Blocking of CUL1 nuclear localization
reduced its NEDD8 modification, resulting in a significant loss
of IkBa ubiquitin ligase activity of CUL1 both in vitro and in
vivo. These results identify a pathway for regulation of CUL1
activity—ROC1 binds to CUL1 and probably collaborates with
its C-terminal sequence to promote nuclear localization of
CUL1, thereby facilitating NEDD8 modification and assembly
of active CUL1 ubiquitin ligase in the nucleus. Three elements
involved in the activation of CUL1 ligase activity—ROC1
binding, NEDD8 modification, and the C-terminal sequence—
are shared by or conserved in most, if not all, cullins, suggest-
ing that this pathway may be commonly utilized in the assembly
and activation of other cullin ligases.
MATERIALS AND METHODS
Plasmids. Full-length mammalian cullin cDNAs were described previously
(31). Human ROC1 cDNA was described previously (33). Cullin mutations were
introduced by site-directed mutagenesis using the Quick-Change kit (Stratagene)
and verified by DNA sequencing. Human NEDD8 cDNA (21) was amplified
from a HeLa cell cDNA library by PCR and subcloned into the pcDNA3 mam-
malian expression vector with a Myc epitope tag.
Cell lines, culture conditions, and cell transfection. Human U2OS and 293T
cells used in this study were cultured in Dulbecco modified Eagle medium,
supplemented with 10% fetal bovine serum in a 37°C incubator with 5% CO2.
Cell transfections were carried out using the Lipofectamine (Gibco-BRL) or
Effectene (QIAGEN) transfection reagents according to the manufacturer’s
instructions (Gibco-BRL) (for U2OS cells) or calcium-phosphate buffer (for
293T cells). For each transfection, 2.5, 5, or 15 mg of total plasmid DNA was used
for each six-well, 60- or 100-mm dish, respectively.
Antibodies, immunochemistry, and indirect immunofluorescence. Procedures
for [35S]methionine metabolic labeling, immunoprecipitation, and immunoblot-
ting have been described previously (11). Indirect immunofluorescence was pre-
viously described in detail (54). Antibodies to human CUL1 and SKP1 (31) and
to human ROC1 (33) were previously described. Monoclonal antihemagglutinin
(a-HA) (12CA5; Boehringer-Mannheim), affinity-purified polyclonal a-HA
(sc-805; Santa Cruz), a-Myc (9E10; NeoMarker), a-FLAG (clone M2, F3165;
Sigma), a-T7 (no. 69522; Novagen), rhodamine red- and fluorescein isothiocya-
nate-conjugated donkey secondary antibodies (Jackson ImmunoResearch Lab-
oratories), and a rabbit polyclonal antibody to NEDD8 (Catalog no. 210-194;
Alexis Biochemicals, San Diego, Calif.) were purchased commercially.
In vitro NEDD8 assays. [35S]methionine-labeled proteins were prepared in
vitro with T7 RNA polymerase using a TNT-coupled reticulocyte lysate system
according to the manufacturer’s recommendation (Promega). Equal amounts of
ROC1 and CUL1 plasmid DNA (0.3 mg) were mixed and were transcribed and
translated together. After incubation for 90 min at 30°C, the reaction mixture was
aliquoted, diluted with the NP-40 buffer, and immunoprecipitated with either
HA or Myc antibody (11). Immunoprecipitates were washed three times with the
same NP-40 buffer, boiled in sodium dodecyl sulfate (SDS) sample buffer con-
taining 0.1 M dithiothreitol (DTT), and electrophoresed on 7.5 to 15% gradient
denaturing polyacrylamide gels followed by autoradiography.
In vitro and in vivo ubiquitin ligase activity assays. The procedure for an in
vitro assay of the ROC- and cullin-associated ubiquitin ligase activity was essen-
tially the same as has been previously described (33, 45). Purified rabbit E1
ubiquitin-activating enzyme was purchased from Affinity Research Products (Ex-
eter, United Kingdom). His-tagged E2 human UbcH5C was purified using nickel
beads (QIAGEN). Ub was prepared by subcloning full-length Ub as a fusion
protein with a six-His tag and protein kinase C recognition site (LRRASV) and
was purified with nickel beads (45). For ubiquitination assays, transfected HA-
tagged wild-type or mutant CUL1 immunocomplexes were immunoprecipitated
with a-HA antibody. Immunocomplexes immobilized on protein A agarose
beads were washed and added to a Ub ligation reaction mixture (30 ml) that
contained 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 2 mM NaF, 10 nM okadaic
acid, 2 mM ATP, 0.6 mM DTT, 0.75 mg of Ub, 60 ng of E1, 300 ng of E2, and
1.2 mg of phosphorylated glutathione S-transferase (GST)–IkBa1–54. Reaction
mixtures were incubated at 37°C for 60 min, terminated by adding 30 ml of 23
Laemmli loading buffer and boiling for 4 min, and resolved by SDS-polyacryl-
amide gel electrophoresis (PAGE) followed by autoradiography to visualize the
ubiquitinated IkBa ladders. For substrate preparation, 36 mg of purified gluta-
thione S-transferase-IkBa (residues 1 to 54) was phosphorylated with an HA
immunocomplex derived from 293T cells transfected with HA-tagged, constitu-
tively active IKKbS177E/S181E kinase. The reaction was carried out in the presence
of 20 mCi of [g-32P]ATP at 37°C for 20 min in a total volume of 60 ml of kinase
buffer (50 mM Tris-HCl [pH 7.4], 5 mM MgCl2, 5 mM ATP, 2 mM NaF, 10 nM
okadaic acid, and 0.6 mM DTT).
For the in vivo IkBa ubiquitination assay, 293T cells on a 100-mm dish were
transfected with plasmids expressing HA-CUL1 (5 mg), Myc-b-TrCP (3 mg),
Myc-ROC1 (3 mg), SKP1 (5 mg), HA-IKKbS177E/S181E (3 mg), FLAG-IkBa (1
mg), and HA-Ub (5 mg). The total amount of plasmid DNA in each transfection
was adjusted to total 25 mg with a pcDNA3 empty vector when needed. Twenty
hours after transfection, cells were treated with the proteasome inhibitor MG132
(25 mM) for 4 h. Cells were then collected, pelleted by centrifugation, lysed in
200 ml of preboiled SDS-lysis buffer (50 mM Tris-HCl [pH 7.5], 0.5 mM EDTA,
1% SDS, 1 mM DTT), and further boiled for an additional 10 min. Lysates were
clarified by centrifugation at 14,000 rpm on a microcentrifuge (5415C; Eppen-
dorf) for 10 min. The supernatant was diluted 10-fold with 0.5% NP-40 buffer
and immunoprecipitated with anti-FLAG antibody (3.6 mg). Immunoprecipitates
were washed three times and resolved on a 7.5 to 15% gradient SDS-PAGE,
followed by immunoblotting with anti-HA antibody (1 mg/ml) or anti-FLAG
antibody (1 mg/ml).
RESULTS
The C-terminal sequence is required for nuclear localiza-
tion of CUL1. The carboxyl terminus is the most highly con-
served region in cullin family members from different organ-
isms (19) (Fig. 1A). In experiments investigating the functional
significance of this highly conserved domain, we noticed that
deletion of the CUL1 C terminus resulted in an altered sub-
cellular localization. Subcellular localization of wild-type hu-
man CUL1 in transfected U2OS cells exhibited heterogeneous
patterns (Fig. 1B), localized predominantly to the nucleus in
most cells (81.9%) (Table 1) and predominantly to the cyto-
plasm in a small percentage of cells (6.5%), and equally dis-
tributed in both the nucleus and the cytoplasm in the remain-
ing cells (11.6%). Similar heterogeneous distribution with
predominant nuclear localization was also seen for endoge-
nous CUL1 (Fig. 1B, column 5). Whether this heterogeneity
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reflects a dynamic trafficking of CUL1 protein or a cell cycle-
dependent regulation has not been investigated. Deletion of 22
C-terminal amino acid residues (CUL1DC22) significantly im-
paired the nuclear accumulation of CUL1, resulting in a pre-
dominantly cytoplasmic accumulation of CUL1 in most cells
(63.2%) and a reduction of predominantly nuclear localization
from 81.9 to 14.5% of the cell population (Table 1 and Fig. 1B,
column 6). To identify the residues required for CUL1 nuclear
accumulation, we mutated several highly conserved residues
and examined their effect on subcellular localization by indi-
rect immunofluorescence. Mutation of two adjacent hydropho-
bic residues, Leu756 and Ile757 (CUL1L756A/I757A), reduced
the nuclear accumulation of CUL1 from 81.9% of cells to
23.6% and increased the population of cells with predomi-
nantly cytoplasmic CUL1 staining from 6.5 to 41.2% (Table 1
and Fig. 1B, column 7). These results indicate that mutations
at Leu756 and Ile757 significantly impaired nuclear accumula-
tion of CUL1 but less severely than the C-terminal 22-residue
deletion, suggesting that additional residue(s) in this region
may also contribute to nuclear accumulation of CUL1.
To determine whether the conserved C termini of other
cullins are also required for nuclear localization, we intro-
duced similar double point mutations at the conserved Leu
and Ile residues into human CUL2 (CUL2L725A/I726A), CUL5
(CUL5L760A/I761A), and mouse CUL4A (mCUL4AL739A/I740A)
and examined their effect on subcellular localization. Like
CUL1, the wild-type CUL2, mCUL4A, and CUL5 are local-
ized predominantly to the nucleus in most cells and to the
FIG. 1. The C-terminal sequence is required for nuclear localization of CUL1. (A) Amino acid sequence comparison of three functional domains, the ROC1 binding
domain, the NEDD8 conjugation site, and the C-terminal sequence involved in both NEDD8 modification and nuclear localization (NEDD8/NL), of six human cullins,
human APC2, and CUL1 from eight different organisms. Hs, Homo sapiens (human); Mm, Mus musculus (house mouse); Dm, Drosophila melanogaster (fruit fly); Dd,
Dictyostelium discoideum (slime mold); Ce, C. elegans (worm); Sp, Schizosaccharomyces pombe (fission yeast); Le, Lycopersicon esculentum (tomato); At, Arabidopsis
thaliana (mouse-ear cress); Sc, Saccharomyces cerevisiae (budding yeast). Shadowed residues denote mutations that were characterized in this study. Asterisks indicate
the stop codon. (B) Subcellular localization of the CUL1 protein was examined by indirect immunofluorescence in untransfected U2OS cells or U2OS cells transiently
transfected with plasmid DNA expressing HA-tagged wild-type and mutant CUL1. (C) Levels of CUL1 expression for wild-type and mutant proteins were examined
by Western blot analysis of transfected U2OS cells.
TABLE 1. Subcellular localization of CUL1 proteinsa
Mutation










None 176/81.9 14/6.5 25/11.6 215
DC22 28/14.5 122/63.2 43/22.3 193
L756A/I757A 43/23.6 75/41.2 64/35.2 182
K720A 186/85.3 4/1.8 28/12.8 218
D610–615 18/7.9 163/71.5 47/20.6 228
Y42A/M43A 182/73.7 10/4.0 55/22.3 247
a U2OS cells were transfected with plasmids expressing HA-tagged wild-type
or mutant CUL1. Thirty-six hours after transfection, cells were fixed and stained
with a monoclonal antibody recognizing HA (12CA5). At least 180 positive cells
were counted for each transfection, and subcellular distribution of HA-tagged
CUL1 was scored into three categories: predominantly nuclear, predominantly
cytosolic, and equally distributed.
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cytoplasm in a smaller population (data not shown). Mutations
at the adjacent Leu and Ile residues reduced nuclear accumula-
tion of all three cullins (data not shown). These results demon-
strate that the C-terminal sequence contains an evolutionarily
conserved element required for efficient nuclear localization of
most, if not all, cullin proteins. Notably, the APC2 protein lacks
this sequence, suggesting a distinct mechanism for regulation of
APC ligase activity.
The transfected cullins described in this study—wild-type
CUL1, the CUL1DC22 and CUL1L756A/I757A mutants, a
NEDD8 modification mutant (CUL1K720A), a ROC1 bind-
ing mutant (CUL1D610–615), and a SKP1 binding mutant
(CUL1Y42A/M43A)—were expressed at similar levels as de-
termined by direct immunoblotting of the total cell lysate de-
rived from each transfected cell population with anti-HA an-
tibody (Fig. 1C, lanes 1 to 6). These results exclude the
possibility that these point mutations or small internal dele-
tions changed CUL1 protein stability or expression levels, re-
sulting in an altered subcellular localization. From these ex-
periments, we conclude that the C-terminal sequence of
human CUL1 contains a signal critically important for CUL1’s
nuclear accumulation. Notably, a slow-migrating and less in-
tense band was detected in cells expressing wild-type CUL1
(Fig. 1C, lane 1) but was not seen or was substantially reduced
in all five CUL1 mutants (lanes 2 to 6). This band was later
confirmed as NEDD8-modified CUL1 (see below), suggesting
a potential link between CUL1 modification by NEDD8 and its
nuclear import and binding with ROC1 and SKP1. Experi-
ments to investigate these possible links are described below.
Blocking nuclear accumulation of CUL1 reduces its modi-
fication by NEDD8. The carboxyl terminus of CDC53 was
previously shown to be required for RUB1 modification of
yeast CDC53 (22). The NEDD8 conjugation site in human
CUL2 has been mapped to Lys residue 689 (46), correspond-
ing to Lys720 in human CUL1 (Fig. 1A). The function of the
C-terminal sequence in promoting nuclear accumulation of
cullin, while distinct from the NEDD8 conjugation site, sug-
gests that nuclear localization and RUB1 or NEDD8 modifi-
cation may be two related events. To test this possibility, we
first sought to confirm the NEDD8 modification site in human
CUL1. Transfected wild-type, HA-tagged CUL1 was resolved
into two forms as determined by coupled immunoprecipitation
and immunoblotting (IP-Western) (Fig. 2A, lane 5), likely cor-
responding to unmodified and NEDD8-conjugated CUL1, re-
spectively. Coexpression with Myc3-NEDD8 resulted in the
appearance of a third, even slower-migrating band (lane 6).
When the same a-HA precipitate was immunoblotted with
a-Myc antibody, the slowest-migrating form, but not the other
two bands, was detected (lane 3), confirming that it corre-
sponds to Myc3-NEDD8-conjugated CUL1. Mutation of Lys
residue 720 (HA-CUL1K720A) abolished both slow-migrat-
ing forms without affecting the fast-migrating band (lane 9),
confirming that the two slow-migrating forms correspond
to NEDD8- and Myc3-NEDD8-conjugated CUL1 and that
Lys720 is the major, if not the only, site for modification by
NEDD8 in CUL1.
To determine whether nuclear accumulation of CUL1 and
its modification by NEDD8 may regulate each other, we ex-
amined NEDD8 modification of mutant CUL1 defective in
nuclear localization and the subcellular localization of mutant
CUL1 lacking the NEDD8 modification site. HA-tagged wild-
type or mutant CUL1 that was defective in nuclear localization
FIG. 2. The CUL1 C-terminal sequence is required for NEDD8 modification. (A) 293T cells were transiently transfected with plasmid vectors expressing
Myc3-NEDD8 and wild-type or mutant CUL1 proteins as indicated. Lysates were prepared 24 h after transfection from each transfected cell population and
immunoprecipitated with a-HA antibody. The precipitates were separated by SDS-PAGE and immunoblotted with a-HA or a-Myc antibodies. The asterisk in lane 4
indicates a nonspecific band cross-reacting with the monoclonal HA antibody. A polyclonal a-HA antibody that avoids this cross-reacting polypeptide was used in
subsequent experiments. (B) 293T cells were transiently transfected with plasmid vectors expressing wild-type or mutant CUL1 proteins as indicated. Lysates were
prepared 24 h after transfection from each transfected cell population and immunoprecipitated with a-HA antibody. The precipitates were separated by SDS-PAGE
and immunoblotted with a-NEDD8 antibody (right panel), and then the same filter was stripped and reblotted with a-HA antibody. K/LI refers to a triple mutation
in CUL1 (K720A/L756A/I757A). ND8, NEDD8.
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(L756A/I757A) or at the NEDD8 modification site (K720A),
or their combination (referred to as K/LI), was transiently
transfected into cultured 293T cells. NEDD8 modification of
transfected CUL1 was determined by direct immunoblotting of
HA immunoprecipitates with either a-HA antibody or a-NEDD8
antibody (Fig. 2B). Mutations in the CUL1 C-terminal sequence
that impaired CUL1 nuclear localization (HA-CUL1L756A/I757A)
consistently caused a considerable decrease, but not disrup-
tion, of NEDD8-conjugated CUL1 (Fig. 2B, lanes 2 and 3; Fig.
6A, lanes 2 and 6, Fig. 7C, lanes 5 and 6; and Fig. 7D, lanes 3
and 4).
NEDD8 modification is not required for CUL1 nuclear lo-
calization. We next examined subcellular localization of a mu-
tant CUL1K720A protein, harboring a mutation at its NEDD8
modification site. Compared with wild-type HA-CUL1 trans-
fected in parallel, mutation at the NEDD8 modification site
(K720A), in contrast to the mutations in the C-terminal se-
quence, had no significant effect on CUL1’s nuclear localiza-
tion (Fig. 3, middle column, and Table 1). CUL1 mutated in
both the C-terminal and NEDD8 conjugation sites (CUL1K/LI)
was still blocked from accumulating in the nucleus (Fig. 3, right
column). Taken together, these observations indicate that
NEDD8 modification is not required for nuclear accumulation
of CUL1.
Mapping the ROC1 binding sequence in CUL1. Both endo-
genously and ectopically expressed ROC1 protein localized
mainly to the nucleus, with lower levels present in the cyto-
plasm (data not shown). We noticed an increase of nuclear
accumulation of cullin proteins when they were cotransfected
with ROC1 but not with APC11 (data not shown), raising the
possibility that ROC1 may facilitate or be required for nuclear
accumulation of cullins. To test this possibility directly, we first
attempted to map the ROC1 binding sequence in order to
identify a ROC1-binding-deficient mutant CUL1. Through a
series of deletion analyses, we mapped a sequence in human
CUL1, between residues 549 and 650, that is sufficient for
binding with ROC1 as determined by reciprocal a-HA-CUL1
and a-ROC1-Myc immunoprecipitation (Fig. 4A, lanes 5 to 8).
A comparison of the intensity of coprecipitated ROC1-Myc
shows that the ROC1 binding affinity of CUL549–650 is very
similar to that of wild-type CUL1 (Fig. 4A, compare lanes 5
and 7), indicating that CUL549–650 contains most, if not all,
ROC1 binding activity. As a control, another CUL1 fragment
containing residues 350 to 493 exhibited no detectable binding
with cotransfected ROC1-Myc (lanes 9 and 10).
Further deletion analyses within this region identified two
internal deletion mutants, CUL1D606–624 (Fig. 4B, lanes 5 and
11) and CUL1D610–615 (lanes 6 and 12), that significantly re-
duced but did not completely disrupt the binding with ROC1
as determined by reciprocal immunoprecipitations. As a con-
trol, disruption of SKP1 association by the mutations at Tyr42
and Met43 (HA-CUL1Y42A/M43A) did not affect the binding of
CUL1 with ROC1, as determined reciprocally by either an-
ti-HA (Fig. 4B, lane 10) or anti-SKP1 (data not shown) im-
munoprecipitation, consistent with the previous finding that
ROC1 and SKP1 bind independently to two separate regions
in CUL1 (33). Six amino acid residues deleted in CUL1
(CUL1D610–615), which resulted in a disruption of ROC1 bind-
ing, are highly conserved among members of cullins from dif-
ferent organisms (Fig. 1A), suggesting that this sequence may
be required for binding of ROC1 to other cullin proteins as
well.
We also determined the effect of disruption of NEDD8 mod-
ification and mutation in the C-terminal sequence of CUL1 on
CUL1’s ability to bind ROC1 (Fig. 4C). Neither the mutation in
the site for modification by NEDD8 (CUL1K720A; Fig. 4C, lanes
2 and 5), the C-terminal mutation (CUL1L756A/I757A; data not
shown), nor their combination (CUL1K/LI; Fig. 4C, lanes 3 and 6)
in CUL1 affects the binding of CUL1 with ROC1, indicating that
FIG. 3. NEDD8 modification is not required for nuclear localization of CUL1. Subcellular localization of proteins was examined in transiently transfected U2OS
cells for wild-type CUL1, mutant CUL1 lacking the NEDD8 modification site (K720A), and CUL1 with a mutated NEDD8 modification site and C-terminal residues
(K720A/L756A/I757A).
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binding of ROC1 to CUL1 is not dependent on CUL1’s nuclear
localization or NEDD8 modification.
ROC1 is required for efficient CUL1 nuclear localization.
Mapping of ROC1 binding sequences and identification of
ROC1 binding mutants of CUL1 allowed us to determine
whether ROC1 is involved in nuclear accumulation of CUL1.
Both CUL1D610–615 and CUL1D606–624 are severely impaired
from entering the nucleus (Fig. 5A). The percentage of cells
with predominantly nuclear staining was reduced from 81.9%
for wild-type CUL1 to 7.9% for CUL1D610–615, and predomi-
nantly cytoplasmic staining increased from 6.5 to 71.5% (Ta-
ble 1), an even more pronounced disruptive effect than that
caused by deletion of the C-terminal 22 residues. Since both
CUL1D610–615 and CUL1D606–624 mutants retain a residual low
level of ROC1 binding activity (Fig. 4), such a prominent dis-
ruptive effect on nuclear accumulation of CUL1 associated
with decreased ROC1 binding suggests the possibility that
ROC1 might not act alone to promote CUL1 nuclear accumu-
lation and that additional unidentified factor(s) may collabo-
rate with ROC1 in this process in a way that may or may not act
in a stoichiometric mode in promoting nuclear accumulation of
CUL1. Disruption of the binding of CUL1 with SKP1 (Y42A/
M43A), on the other hand, had only a slight effect on CUL1’s
nuclear accumulation (Fig. 5A). The percentage of cells
with predominantly nuclear CUL1 staining was reduced from
81.9% for the wild type to 73.7% for CUL1Y42A/M43A (Table
1). Whether this result reflects a minor contribution of SKP1 to
the nuclear accumulation of CUL1 has not been determined.
Both CUL1D606–624 and CUL1D610–615 still bind with SKP1 as
well as wild-type CUL1 does (Fig. 4B, lanes 11 and 12), and
both can be modified efficiently by NEDD8 in vitro (Fig. 6B),
arguing against the possibility that impairment of nuclear ac-
cumulation of CUL1 by mutations at the ROC1 binding site is
caused by an overt protein conformational change or aggrega-
tion, as opposed to a loss of ROC1 binding. These observations
suggest that ROC1 is required for efficient nuclear localization
of CUL1.
Requirement of both ROC1 and C-terminal sequence for
nuclear accumulation of CUL1. The finding that mutation of
CUL1 either in the ROC1 binding region or in the C-terminal
sequence impaired CUL1 nuclear accumulation led us to de-
termine whether these two signals are functionally redundant
or collaborative. In a small fraction of transfected cells express-
ing very high levels of cullins, we noticed a cytoplasmic staining
that was more intense than nuclear staining (data not shown).
In cells cotransfected with ROC1, however, CUL1 was mainly
localized to the nucleus even when they were expressed at high
levels (Fig. 5B). These observations are consistent with the
finding that ROC1 promotes, and may even act as a rate-
limiting factor for, nuclear accumulation of cullins. When the
C-terminal mutant CUL1 was coexpressed with ROC1, how-
ever, it remained localized predominantly in the cytoplasm
despite high levels of ROC1 expression (Fig. 5B). In most cells
examined, we noticed that nuclear staining of HA-ROC1 ap-
peared to be lower in cells expressing C-terminally mutated
cullins than in cells expressing wild-type cullins, suggesting that
mutations in the C-terminal sequence of cullins not only im-
paired their nuclear accumulation but also resulted in a cyto-
plasmic retention of their associated ROC1. These results,
together with the observation that the mutant CUL1D610–615
that is deficient in ROC1 binding is impaired from entering the
nucleus despite containing an intact C-terminal sequence (Fig.
5A), suggest that the cis-acting C-terminal sequence and trans-
acting ROC1 binding are both needed for nuclear accumula-
tion of cullin.
ROC1 promotes NEDD8 modification of CUL1 in vivo. The
finding that ROC1 promotes cullin nuclear accumulation led
us to determine the role of ROC1 in regulating NEDD8 mod-
ification of cullins. HA-tagged wild-type or mutant CUL1 was
either singly transfected or cotransfected with Myc-ROC1 into
293T cells. Similar levels of Myc-ROC1 protein were expressed
in each transfection, as verified by a-Myc IP-Western blotting
(Fig. 6A, bottom panel). Modification of transfected HA-
CUL1 by NEDD8 was determined by immunoprecipitation
FIG. 4. Mapping the ROC1 binding region in CUL1. 293T cells transiently transfected with the indicated plasmids expressing Myc-tagged ROC1 and two
HA-tagged CUL1 fragments or several mutant CUL1s were pulse-labeled with [35S]methionine. Lysates prepared from transfected cells were immunoprecipitated with
either a-Myc or a-HA antibody and resolved by SDS-PAGE, followed by autoradiography. (A) Mapping the ROC1 binding region in CUL1. (B) Characterization of
ROC1 binding mutant CUL1s. (C) NEDD8 modification and nuclear localization of CUL1 are not required for CUL1-ROC1 binding.
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with a-HA antibody followed by immunoblotting with ei-
ther a-HA or a-NEDD8 antibody. Cotransfection with ROC1
increased the levels of NEDD8-conjugated CUL1 (Fig. 6A,
compare lanes 2 and 3), indicating that ROC1 can promote
modification of CUL1 by NEDD8 in vivo. More intense
NEDD8-conjugated CUL1 was seen with the a-HA antibody
than with the a-NEDD8 antibody due to the higher affinity of
the HA antibody. Mutation in the ROC1 binding region (HA-
CUL1D610–615) substantially reduced the levels of NEDD8-con-
jugated CUL1 (Fig. 6A, compare lanes 2 and 4). Consistent
with residual ROC1 binding activity in the CUL1D610–615 mu-
tant (Fig. 4B), overexpression of ROC1 also exhibited a pro-
moting effect on NEDD8 modification of CUL1D610–615, but
the level of NEDD8-conjugated CUL1D610–615 is substantially
lower than that of NEDD8-conjugated wild-type CUL1 (Fig.
6A, compare lanes 3 and 5). Similarly, overexpression of
ROC1 also increased NEDD8 modification of the CUL1 C-
terminal mutant (CUL1L756A/I757A) (Fig. 6A, compare lanes 6
and 7), but the level of NEDD8-conjugated CUL1L756A/I757A is
greatly reduced from that of wild-type CUL1, both with or
without coexpression of ROC1 (Fig. 6A, compare lanes 6 and
7 with lanes 2 and 3). NEDD8 modification was completely
abolished by the mutation at Lys720 (CUL1K720A) and was not
detectably restored by the overexpression of ROC1 (lanes 8
and 9). These results demonstrate that ROC1 promotes
NEDD8 modification in vivo and are consistent with a recent
report that RUB1 or NEDD8 modification of both yeast
CDC53 and human CUL2 in yeast or insect cells is dependent
on the presence of ROC1 (16).
In vitro NEDD8 modification requires the CUL1 C-terminal
sequence but not ROC1. Mutations both in the CUL1 C-
terminal sequence and in the ROC1 binding region impaired
nuclear accumulation of CUL1 and decreased modification of
CUL1 by NEDD8, suggesting a link between CUL1 nuclear
accumulation of NEDD8 modification. These findings also
raised the question of whether the C-terminal sequence and
ROC1 are involved in two apparently separate events: pro-
moting CUL1 nuclear accumulation and promoting NEDD8
modification. To address this question, we examined in vitro
NEDD8 modification of wild-type and mutant CUL1 in rabbit
reticulocyte lysate. Consistent with previous reports (23, 34), in
vitro synthesized wild-type HA-CUL1 migrates as two forms: a
fast-migrating major band corresponding to unmodified CUL1
and a slow-migrating minor form corresponding to NEDD8-
conjugated CUL1 (Fig. 6B, lane 2). Mutation at Lys720 abol-
ished the slow-migrating form without affecting the fast-mi-
grating band (lane 5), confirming the NEDD8 modification in
this assay. Mutation in the C-terminal sequence of CUL1
(L756A/I757A) greatly reduced levels of NEDD8-conjugated
CUL1 (lane 4), indicating that the C-terminal sequence is
required for both CUL1 nuclear accumulation and NEDD8
modification.
In contrast, mutations in the ROC1 binding region, both
CUL1D610–615 (Fig. 6B, lane 6) and CUL1D606–624 (lane 7), had
no detectable effect on NEDD8 modification, nor did addition
of ROC1 have any visible effect on the levels of CUL1-NEDD8
conjugates (lane 3). Introduction of a mutation at the NEDD8
conjugation site, Lys720, into the ROC1-binding mutant
FIG. 5. ROC1 is required for nuclear accumulation of CUL1. (A) Subcellular localization of wild-type and mutant CUL1 proteins with disrupted ROC1 binding
(D610–615 and D606–624) or SKP1 binding (Y42A/M43A) was examined in transiently transfected U2OS cells. (B) The CUL1 C-terminal sequence and ROC1 are
both required to mediate CUL1 nuclear accumulation. U2OS cells were transiently cotransfected with plasmids expressing HA-ROC1 with either wild-type or
C-terminal mutant CUL1. Subcellular localization of both transfected ROC1 and CUL1 protein was examined by indirect immunofluorescence with either a-HA or
a-Myc antibody. Cell nuclei were stained with 49,69-diamidino-2-phenylindole. Note that overexpression of ROC1 is unable to promote nuclear accumulation of
C-terminal mutant CUL1.
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CUL1D606–624 (CUL1D606–624/K720A) completely abolished modi-
fication by NEDD8 (lane 8), confirming NEDD8 modification
on the CUL1D606–624 mutant. To further confirm ROC1-inde-
pendent NEDD8 modification of CUL1 in vitro, we examined
in vitro NEDD8 modification of a deletion mutant CUL1 con-
taining only the C-terminal 149 residues (CUL1C149), which
exhibits undetectable ROC1 binding activity (Fig. 6C). In vitro-
translated HA-CUL1C149 migrates as two bands, a major 22-
kDa form and a less intense 30-kDa form (Fig. 6B, lane 9).
Introduction of the K720A (HA-CUL1C149/K720A) mutation
abolished the 30-kDa form without affecting the 22-kDa band,
indicating that the 30-kDa form corresponded to NEDD8-
modified HA-CUL1C149 (Fig. 6B, lane 10).
In vitro-translated CUL1 was also modified by similarly in
vitro-translated NEDD8, as seen by the appearance of a third
slow-migrating HA-CUL1 band after mixing of in vitro-trans-
lated Myc3-NEDD8 with wild-type HA-CUL1 (Fig. 6B, lane
11) but not with the HA-CUL1K720A mutant (lane 12). In
vitro-translated Myc3-NEDD8 was efficiently conjugated with
the ROC1-binding-deficient HA-CUL1D606–624 mutant (Fig.
6B, lane 14) but not with a double HA-CUL1D606–624/K720A
mutant (lane 15), further confirming ROC1-independent
NEDD8 modification of CUL1 in vitro. As in the maturation
and conjugation of ubiquitin, the C terminus of newly synthe-
sized human NEDD8 contains five additional residues, Gly-
Gly-Leu-Arg-Glu, following the conserved Gly76, that are
cleaved during maturation in order to expose the Gly76 for
conjugation. It was shown previously that Gly76 of NEDD8
is necessary for conjugation to other proteins (15). Mutat-
ing NEDD8 Gly76 to alanine (Myc3-NEDD8G76A) complete-
ly abolished the conjugation of NEDD8 with both wild-type
CUL1 (lane 13) and the ROC1-binding-deficient CUL1D606–624
mutant (lane 16) without any detectable effect on the conju-
gation of both CUL1 proteins with the wild-type NEDD8 pres-
ent in the reticulocyte lysate. From these results, we conclude
that ROC1 is not required for NEDD8 modification in vitro.
NEDD8 modification is required for efficient CUL1 ubiq-
uitin ligase activity. To determine the functional consequence
of CUL1 nuclear accumulation and NEDD8 modification, we
examined in vitro ubiquitin ligase activity of mutant CUL1
mutated in the C-terminal sequence, in the NEDD8 modifica-
tion site, and in ROC1 binding using IkBa as a substrate.
HA-tagged wild-type or mutant CUL1 was cotransfected with
SKP1 and the IkBa-targeting F box protein b-TrCP. The ubiq-
uitin ligase activity of CUL1 was precipitated with an a-HA
antibody and assayed using phosphorylated IkBa as a sub-
strate. As previously reported (33, 45), the wild-type CUL1
immunocomplex exhibited high levels of IkBa ubiquitination
activity that is dependent on both E1 and E2-Ubc5 (Fig. 7A,
lanes 1 to 3). Mutations in the C-terminal sequence (L756A/
I757A) (lane 5), at the NEDD8 modification site of CUL1
(K720A) (lane 4), or their combination (K/LI) (lane 6) sub-
stantially reduced the ubiquitin ligase activity of CUL1. A
FIG. 6. ROC1 promotes NEDD8 modification of CUL1 in vivo but not in
vitro. (A) 293T cells were transiently cotransfected with plasmids expressing
Myc-tagged ROC1 and HA-tagged wild-type or mutant CUL1 proteins as indi-
cated. Twenty-four hours after transfection, lysates were prepared from each
transfected cell population and immunoprecipitated with a-HA or a-myc anti-
bodies. The a-HA precipitates were separated by SDS-PAGE and immunoblot-
ted with a-HA antibody, and then the same filter was stripped and reblotted with
a-NEDD8 antibody. The a-Myc precipitates after SDS-PAGE were blotted with
a-Myc to verify the expression of Myc-ROC1. (B) In vitro assay for modification
of CUL1 by NEDD8. Wild-type or mutant CUL1 proteins were synthesized
together in vitro with either Myc3-ROC1 or Myc3-NEDD8 through a coupled in
vitro transcription and translation system (TNT; Promega) in rabbit reticulocyte
lysate in the presence of [35S]methionine. HA-CUL1, Myc3-ROC1, and Myc3-
NEDD8 proteins were immunoprecipitated using HA and Myc antibodies, re-
spectively, and resolved by SDS-PAGE. Note that the addition of ROC1 (lane 3)
or mutation in the ROC1 binding region of CUL1 (D610–615 and D606–624,
lanes 6 and 7) had no obvious effect on NEDD8 modification of CUL1 in vitro.
(C) CUL1-ROC1 binding assay. Wild-type CUL1 and a CUL1 deletion mutant
containing the C-terminal 149 residues were cotransfected with ROC1-Myc into
293T cells. CUL1-ROC1 binding was determined reciprocally by immunopre-
cipitation with either HA or Myc antibodies.
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substantial decrease, but not complete abolition, of ligase ac-
tivity by the disruption of NEDD8 modification indicates that
NEDD8 modification is important, but not absolutely re-
quired, for CUL1 ubiquitin ligase activity. A mutation in the
ROC1 binding region (D610–615) almost completely abro-
gated the ligase activity of CUL1 (Fig. 7A, lane 7). The more
disruptive effect on the ligase activity by the mutation in the
ROC1 binding sequence than by the mutation at the NEDD8
modification site indicates that in addition to promoting nu-
clear accumulation and NEDD8 modification, ROC1 also has
an additional function in activating CUL1 ligase activity.
To further confirm the reduction of ubiquitin ligase activity
by the mutations affecting CUL1’s nuclear accumulation and
modification by NEDD8, we established a condition to assay in
vivo IkBa ubiquitination by CUL1 and determined the in vivo
IkBa ubiquitin ligase activity of wild-type and mutant CUL1.
FLAG-IkBa was cotransfected with a constitutively active mu-
tant IkBa kinase (IKKbS177E/S181E), b-TrCP, ROC1 and SKP1,
CUL1, and HA-tagged ubiquitin. Twenty hours after transfec-
tion, cells were treated with the proteasome inhibitor MG132,
lysed in a preboiled SDS (1%) lysis buffer, and boiled for
another 10 min. Whole cell lysate was then diluted with NP-40
buffer to reach a final concentration of 0.1% SDS, immuno-
precipitated with a-FLAG antibody, resolved by SDS-PAGE,
and immunoblotted with a-HA or with a-FLAG antibodies. A
high-molecular-weight smear characteristic of ubiquitination
was detected on both immunoblots (Fig. 7B, lane 5) but was
not detected when HA-Ub (lane 2) or FLAG-IkBa (lane 3)
was omitted from transfection, indicating that the high-molec-
ular-weight smear corresponds to in vivo ubiquitinated IkBa.
The appearance of ubiquitinated IkBa was not seen when
CUL1, b-TrCP, ROC1, and SKP1 were omitted (lane 1), con-
firming an SCFb-TrCP-dependent ubiquitination (44, 48, 49).
Dropout of IKKb from transfection substantially reduced the
level of phosphorylated IkBa (Fig. 7B, right panel, compare
lane 4 with lanes 2 and 5 to 7) and the level of ubiquitination
of IkBa (lane 4), confirming the dependency of IkBa ubiquiti-
nation on its phosphorylation by IKKb (28, 53). A low level of
IkBa ubiquitination was still visible when IKKb was omitted
from transfection, which is probably attributable to a residual
level of endogenous IKKb. The levels of ectopically expressed
SKP1, ROC1, and CUL1, the reduction of NEDD8 modifica-
tion by the L756A/I757A mutation, and the disruption of
NEDD8 modification by the K720A mutation were confirmed
by sequential immunoprecipitation and immunoblotting (Fig.
7C).
Consistent with the in vitro assay, the in vivo IkBa ubiquitin
ligase activity of CUL1 was reduced by both the L756A/I757A
(Fig. 7B, lane 6) and the K720A (lane 7) mutations. In contrast
to the in vitro assay in which the CUL1L756A/I757A and the
CUL1K720A mutants exhibited similarly reduced levels of ligase
activity, we have consistently observed a more pronounced
effect of the K720A mutation than of the L756A/I757A muta-
tion on the in vivo IkBa ubiquitin ligase activity of CUL1. In
fact, under this in vivo assay condition, the level of ubiquiti-
nated IkBa with NEDD8-deficient CUL1K720A is close to that
seen in transfection without the IKKb kinase (comparing lanes
4 and 7). The basis for this difference between in vivo and
in vitro assays has not been determined, but it could be caused
by the higher levels of the substrate (phosphorylated IkBa)
in vivo than in vitro. This observation also suggests that the in
vivo assay may be more sensitive than the in vitro assay in
detecting the change of CUL1 ubiquitin ligase activity.
Modification by NEDD8 is not required for the assembly of
the SCF complex. Diminishing of CUL1 ubiquitin ligase activ-
ity by mutations disrupting NEDD8 modification led us to ask
whether a deficiency in NEDD8 modification impairs the as-
sembly of the SCF complex or impedes interaction of ligase
with the substrate. HA-tagged wild-type or mutant CUL1 was
cotransfected with SKP1, ROC1, b-TrCP, and IkBa. Interac-
tion of CUL1 with SKP1 and IkBa was examined by IP-West-
ern blotting (Fig. 7D). The wild type and both the L756A/
I757A and K720A mutants of CUL1 coimmunoprecipitated
similar amounts of SKP1. SKP1 bound to both NEDD8-modi-
fied and unmodified forms of CUL1. The ratio of these two
forms of CUL1 present in SKP1 immunocomplexes was similar
to that seen in CUL1 immunocomplexes, suggesting that SKP1
does not preferentially associate with either form of CUL1.
Consistently, SKP1 immunocomplexes derived from cells trans-
fected with wild-type and mutant CUL1 contained similar
amounts of CUL1. These results indicate that disruption of
NEDD8 modification did not affect CUL1-SKP1 interaction.
Likewise, the wild type and both the L756A/I757A and K720A
mutants of CUL1 coimmunoprecipitated similar amounts of
IkBa, and reciprocally, IkBa immunocomplexes contained
perhaps even higher levels of mutant CUL1K720A than wild-
type CUL1. These results indicate that a deficiency of NEDD8
modification did not affect the assembly of SCF complexes, nor
did it impede the interaction of SCF complexes with the sub-
strate.
DISCUSSION
In this report we present evidence suggesting a novel path-
way for regulation of CUL1 ubiquitin ligase—ROC1 and the
CUL1 C-terminal sequence mediate CUL1 nuclear accumula-
tion, promoting CUL1 modification by NEDD8 and ligase
activation (Fig. 8). This pathway contains four previously un-
recognized features. First, the CUL1 C-terminal sequence is
required for both nuclear accumulation and NEDD8 modifi-
cation. Second, ROC1 binding per se is not required for CUL1
modification by NEDD8, but it indirectly promotes NEDD8
modification by promoting CUL1 nuclear accumulation. Third,
CUL1 nuclear accumulation facilitates its modification by
NEDD8. Last, NEDD8 modification is important for efficient
CUL1 ubiquitin ligase activity in vivo.
Dual function of the CUL1 C-terminal sequence in nuclear
accumulation and NEDD8 modification. The site for NEDD8
modification has been mapped to Lys689 in human CUL2 (46),
corresponding to Lys720 in human CUL1 or Lys760 in yeast
CDC53. Deletion of the C-terminal 21 residues (794 to 814)
from yeast CDC53, downstream of Lys760, abrogates RUB1
modification (22). In agreement with these reports, we have
confirmed that a mutation at Lys720 of human CUL1 abol-
ished its NEDD8 modification (Fig. 2A) and found that dele-
tion of or mutation in the C-terminal 22 residues (Fig. 1, 2, and
6) of human CUL1 severely reduced NEDD8 modification.
Hence, the very C-terminal sequence does not contain the site
of, but may play a regulatory role for, NEDD8 modification of
CUL1 or CDC53.
Unexpectedly, we found that deletion of the C-terminal 22
residues or mutations at two conserved amino acids in this
22-residue region impaired nuclear accumulation of CUL1.
The mechanism underlying the function of the C-terminal se-
quence in mediating CUL1 nuclear accumulation is unknown
at present. This sequence has not been determined to be in-
volved in the interaction with any known cullin-interacting
proteins, such as SKP1, ROC1, or CDC34. The C-terminal
sequences of different cullins are highly conserved and do not
resemble the classical nuclear localization signal (NLS), which
is characterized by a cluster of basic residues, as exemplified by
the NLS of the SV40 large T antigen (PKKKRKV). The C-
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terminal 22-amino-acid sequence of CUL1 has an acidic pI of
4.2 and contains only three scattered basic residues, K759,
R764, and a nonconserved K769. On the other hand, there are
eight hydrophobic residues that are highly conserved in other
cullins (Fig. 1A), and mutation of two of these conserved
hydrophobic residues blocks nuclear accumulation of CUL1
and three other cullins examined (data not shown). Although
it is formally possible that the cullin C-terminal sequence con-
tains a nonclassical autonomous NLS to mediate import of
cullin into the nucleus, this seems to be unlikely, given that
mutant CUL1s defective in ROC1 binding, while retaining the
intact C-terminal sequence, are impeded from nuclear accu-
mulation.
Blocking nuclear accumulation of CUL1, by mutations ei-
ther in the C-terminal region of CUL1 or in the ROC1 binding
region, is associated with defective NEDD8 modification of
CUL1. Although blocking of CUL1 nuclear accumulation
could sufficiently explain the severe reduction of NEDD8 mod-
ification by the deletion of or mutation in the C-terminal se-
quence, our in vitro assay suggests that the CUL1 C-terminal
sequence additionally contains another yet-to-be-identified ac-
tivity required for NEDD8 modification. Mutations in the C-
terminal sequence of CUL1 substantially reduced its conjuga-
tion by NEDD8 in vitro in a rabbit reticulocyte lysate (Fig. 6B).
That the mutation at the NEDD8 modification site (CUL1K720A)
has no detectable effect on CUL1 nuclear accumulation argues
against the possibility that NEDD8 modification plays any sig-
nificant role in CUL1 nuclear accumulation. We speculate that
a NEDD8 conjugation activity binds to the C-terminal se-
quence of CUL1 and may act to retain CUL1 in the nucleus.
Mutation in the CUL1 C-terminal sequence, but not the mu-
tation at the NEDD8 modification site, disrupts this binding,
resulting in a defect in both NEDD8 modification and nuclear
retention. Clearly, the function of the cullin C-terminal se-
quence, including the binding with additional yet-to-be-identi-
fied cullin-interacting protein(s), needs to be further investi-
gated.
ROC1 promotes NEDD8 modification by facilitating nu-
clear accumulation of CUL1. Overexpression of ROC1 in-
creased the levels of NEDD8-conjugated CUL1, and converse-
ly, mutations in the ROC1 binding region substantially reduced
the levels of NEDD8-CUL1 conjugates (Fig. 6A). These re-
sults indicate a function of ROC1 in promoting NEDD8 mod-
ification of CUL1 and are consistent with and provide ad-
ditional support for a recent report that reached a similar
conclusion (16). Kamura et al. demonstrated that in vitro con-
jugation of yeast CDC53 with yeast glutathione S-transferase-
RUB1 depends on the coexpression of Rbx1 (ROC1) with
CDC53. The mechanism by which ROC1 promotes RUB1 or
NEDD8 modification of cullins was unclear, but it was sug-
gested that ROC1 may recruit the RUB1-, NEDD8-conjugat-
ing enzyme E2-Ubc12 to cullins or induce conformational
changes in cullins to allow the access of Ubc12 to the RUB1 or
NEDD8 modification site (16). Our results suggest that ROC1
promotes NEDD8 modification of CUL1 by promoting CUL1
nuclear accumulation, but ROC1 per se is not required for
NEDD8 modification. Four lines of evidence collaboratively
support this conclusion. First, mutation in the CUL1 C-termi-
nal sequence that impaired its nuclear accumulation had no
detectable effect on CUL1-ROC1 association (Fig. 4C), sug-
gesting that ROC1 can form a complex with CUL1 in the
cytoplasm. Second, overexpression of ROC1 increased CUL1
nuclear accumulation and NEDD8 modification (Fig. 6A).
Third, mutations in CUL1 disrupting ROC1 binding resulted
in a decreased nuclear accumulation and NEDD8 modification
of CUL1. Last, in vitro modification of CUL1 by NEDD8 was
not affected by the addition of ROC1 or by mutations in CUL1
disrupting ROC1 binding (Fig. 6B) and can occur efficiently
using a 149-residue C-terminal CUL1 fragment devoid of
FIG. 8. A model for cullin ubiquitin ligase activation. Cytoplasmically lo-
cated CUL1 associates with ROC1 and is promoted to enter into and accumulate
in the nucleus. CUL1 nuclear accumulation also requires a C-terminal sequence
in CUL1 through an unknown mechanism (represented by a question mark).
Once inside the nucleus, CUL1 becomes covalently modified with NEDD8
(ND8), resulting in efficient CUL1 ubiquitin ligase activity. NEDD8 modification
is presumed to induce a conformational change in CUL1 to facilitate or stabilize
CUL1-ROC1-E2 binding.
FIG. 7. NEDD8 modification is required for IkBa ubiquitin ligase activity of CUL1. (A) In vitro IkBa ubiquitination. Purified IkBa was phosphorylated with IKKb
and incubated with a-HA immunocomplexes derived from 293T cells cotransfected with plasmids expressing SKP1, FLAG-tagged b-TrCP, and HA-tagged wild-type
or various mutant CUL1 proteins as indicated. Reactions were incubated at 37°C for 60 min, terminated by adding 30 ml of 23 Laemmli loading buffer, boiled for 4
min, and resolved by SDS-PAGE followed by autoradiography to visualize the ubiquitinated IkBa ladders. (B) In vivo IkBa ubiquitination. 293T cells were transfected
with the indicated plasmids, including constitutively active IKKbS177E/S181E. Twenty hours after transfection, cells were treated with the proteasome inhibitor MG132
for 4 h prior to cell lysis. Cells were lysed into a 1% SDS-containing buffer and boiled for 10 min. Lysates were then diluted to 0.1% SDS and immunoprecipitated with
anti-FLAG antibody, and washed immunoprecipitates were resolved by SDS-PAGE, followed by immunoblotting with anti-HA or anti-FLAG antibodies. Exposure
time was 1 min. The asterisk indicates a nonspecific protein precipitated by the anti-FLAG antibody. (C) The levels of ectopically expressed SKP1, Myc-ROC1,
HA-CUL1, and NEDD8 modification were examined by IP-Western blotting. Because the HA-Ub plasmid was included in the transfection, the level of ectopically
expressed HA-CUL1 was determined by immunoprecipitation with an a-CUL1 antibody that detected both endogenous CUL1 and CUL1-NEDD8 conjugates, as well
as transfected HA-CUL1 and HA-CUL1-NEDD8 conjugates. (D) Interaction of SKP1 and IkBa with wild-type and mutant CUL1s. 293T cells were transfected with
the indicated plasmids. Whole cell lysates were prepared using NP-40 lysis buffer and immunoprecipitated with the indicated antibodies, followed by SDS-PAGE and
immunoblotting.
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ROC1 binding capability (Fig. 6B and C). From these results,
we conclude that ROC1 is not required for NEDD8 modifica-
tion in vitro.
How ROC1 promotes CUL1 nuclear accumulation is not
clear. Nuclear accumulation of a protein is the result of several
regulated processes, including nuclear import, retention, and
export. There is the possibility that ROC1 could bind to CUL1
in the cytoplasm and escort CUL1 into the nucleus. Alterna-
tively, ROC1 could act as a nuclear retention factor for nuclear
localization of CUL1. ROC1 alone, however, is not sufficient to
localize CUL1 in the nucleus. Nuclear accumulation of mutant
CUL1 that is defective in the C-terminal sequence, while re-
taining the intact ROC1 binding activity, is impaired (Fig. 3)
and cannot be restored by the overexpression of ROC1 (Fig.
5B). These observations suggest that nuclear accumulation of
cullin involves at least two separate signals: a cis-acting C-
terminal sequence and a trans-acting ROC1 factor. Whether
these two signals function collaboratively (e.g., one promotes
nuclear import and one functions in nuclear retention) or in a
regulatory manner (e.g., ROC1 may facilitate the binding of an
importin receptor to the C-terminal sequence of CUL1) re-
mains to be determined. It also should be pointed out that our
results do not suggest that promoting nuclear accumulation
and NEDD8 modification of cullin are the main functions of
ROC1 as an essential subunit of cullin ligases. This is made
evident by the observation that mutant CUL1 that is defective
in ROC1 binding (CUL1D610–615) loses virtually all its IkBa
ubiquitin ligase activity, whereas mutant CUL1 that is defec-
tive in nuclear accumulation and/or NEDD8 modification re-
tains a considerably higher amount of ligase activity (Fig. 7).
Regulation of cullin ligase activity by nuclear localization
and NEDD8 modification. Deficiency in NEDD8 modification
results in a significant reduction of CUL1 ubiquitin ligase ac-
tivity (32, 35, 37, 39) (Fig. 7). It is not entirely clear how nuclear
accumulation of CUL1 facilitates its modification by NEDD8
and how NEDD8 modification results in activation of CUL1
ubiquitin ligase. Both the NEDD8-activating E1 protein AXR1
(38) and NEDD8 itself (15) are localized primarily in the
nucleus, suggesting the possibility that nuclear accumulation
may provide CUL1 with access to a NEDD8 conjugating ac-
tivity. ROC1 promotes association of CDC34 with CDC53/
CUL1 when coexpressed in insect cells (43), and CDC34 is
localized predominantly in the nucleus (Y.Z. and Y.X, unpub-
lished observation), suggesting the possibility that ROC1-pro-
moted nuclear accumulation and NEDD8 modification may
facilitate or stabilize the binding of E2 with CUL1 in the
nucleus, leading to the assembly of active CUL1 ubiquitin
ligase. The requirement of nuclear accumulation and NEDD8
modification for optimal CUL1 ligase activity toward IkBa, a
cytoplasmic protein, argues against the idea that nuclear accu-
mulation and NEDD8 modification play a role in substrate
targeting. We suggest that the assembly of active CUL1 ligase
is not coupled with and is likely separated from the access to its
substrate. Our results demonstrate that activation of CUL1
ligase requires a nuclear event and implies a requirement for,
and potentially a regulatory step associated with, nuclear ex-
port of activated CUL1 ubiquitin ligase.
Notably, three elements involved in the regulation of CUL1
nuclear localization and ligase activation—ROC1 binding,
NEDD8 modification, and the requirement of the C-terminal
sequence—are shared by or highly conserved in most, if not all,
cullins. We suggest that this pathway may be commonly uti-
lized in the assembly and activation of other cullin ligases.
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